This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
8/9/2022
Ladies and gentlemen, thank you for standing by. Welcome to the Infinity Pharmaceuticals conference call to discuss the company's second quarter 2022 financial results and business update. My name is Joseph, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. There will be a question and answer session to follow. Please be advised, this call is being recorded at Infinity's request. Now, I would like to introduce your host for today's call, Jane Kaufman. Please go ahead.
Thank you, Joseph, and good afternoon, everyone. Welcome to today's call to discuss our recent business progress and review of our second quarter 2022 financial results and company highlights. On the call with me today are Adeline Perkins, Chief Executive Officer and Chair, Larry Block, President, and Robert Alaria, Jr., Chief Medical Officer. We'll open up the call for Q&A following our remarks. The press release issued today details our financial results and is available on our website at INFI.com. Please note that during this call, we may make forward-looking statements about our future expectations and plans, including clinical development objectives, the therapeutic potential of our product candidates, our strategic plans, and financial projections. Our actual results may differ materially from what we project today due to a number of important factors, including the considerations described in the risk factor section of our annual report on Form 10-K for 2021 and in other filings we make with the SEC. These forward-looking statements represent our views only as of today, and we caution you that we may not update them in the future, whether as a result of new information, future events, or otherwise. I'd like to turn the call over to Adeline. Thanks, Jane.
And thank you to everyone for joining us today to review Infinity's second quarter 2022 business update. Our goal at Infinity has long been to bring again a list to patients who need better treatment, especially those who have derived little to no benefit from the first generation of immuno-oncology therapies. To achieve this goal, as we discussed on our most recent call last May, we are focused on expanding the clinical evaluation of aganalysib and additional solid tumors to maximize its value for patients and thereby for shareholders, and we are pursuing potential partnerships to enable this. We have two objectives in partnering. First, to expand the development of aganalysib across a broad array of solid tumors with a partner who shares our belief in the magnitude of the aganalysib opportunity and is willing to fund an extensive R&D program, potentially combining aganalysib with prospective partners' drugs to create differentiated treatment regimens. Second, to establish a partnership structure that enables the creation of meaningful value for Infinity shareholders. Since our last quarterly call, we have completed our mid-year strategic review and we've made the decision that we put a partnership in place prior to initiating new clinical trials for a couple of key reasons. One is that we are in discussions with multiple potential partners and given the breadth of activity we've seen with again ELISA, we have multiple development options. As such, collaborating with prospective partners on our organolism clinical development strategy so that we can accommodate their input on the prioritization and design of new studies, including decisions on which combination drug partners to use, is very constructive. In addition, and importantly given current market dynamics, it has allowed us to increase our 2022 year-end cash guidance and extend our cash runway into 2024. Prior to starting new studies, we are focusing our operational resources on our ongoing clinical trials, MERIO-1, MERIO-3, and MERIO-275. Clinical and translational data we have presented from these studies show that aganalysib is a unique immuno-oncology therapeutic candidate for three notable reasons. we have a first-in-class therapy with on-target activity and translational data showing that aganalysib reprograms macrophages in the tumor microenvironment, reduces immune suppression, and activates an anti-cancer immune response. Two, the clinical data with aganalysib have demonstrated prolonged progression-free survival and extended overall survival over current standards of care and multiple indications, including in a randomized control trial that allows us to see the distinct contribution of aganalysib over its combination drug partners. Three, and very importantly, aganalysib has been shown to have an acceptable and manageable safety profile in combination with other drugs, including in two and three drug combination regimens. Reflective of these key attributes Today, we are pleased to report positive updated results from the Mario 275 two-year overall survival analysis in patients with urothelial cancer whose tumors progressed after treatment with a platinum-based chemotherapy regimen. We continue to see very encouraging and durable evidence of survival benefit over the standard of care control arm in this study with no new safety signals during the extended period of treatment, which Rob will review in detail. By the end of this year, we will also review updated PFS data from our MARIO3 trial in frontline triple negative breast cancer patients with both PD-L1 high and PD-L1 low tumors, which meaningfully will be a full year more mature since our last data cut in October of 2021. We are increasingly encouraged by the data across a wide range of indications, lines of therapy, and combinations, which continue to show a consistent trend of improved outcomes for patients in areas of great unmet need that Rob will now review.
You're reading a preview of the INFI Q2 2022 earnings call.
Free account.
